The Ascites Market is expanding due to the rising prevalence of liver cirrhosis, cancer-related complications, and chronic kidney diseases. Ascites, the abnormal buildup of fluid in the abdomen, is increasingly diagnosed worldwide, particularly among patients with advanced liver disorders. The global ascites market reached USD 2.25 Billion in 2025 and is projected to grow at a CAGR of 4.30% from 2026 to 2035, reaching approximately USD 3.43 Billion by 2035.

Key growth drivers include increasing healthcare awareness, rising disposable incomes, rapid urbanization, and growing R&D activities focused on innovative therapies. Improved access to diagnostic imaging such as ultrasound, CT scans, and MRI is also contributing to early detection and treatment.

How Big Will the Ascites Market Be by 2035?

By 2035, the Ascites Market is anticipated to attain a value of USD 3.43 Billion. Growth is supported by expanding hospital infrastructure and advancements in minimally invasive procedures like paracentesis. The increasing burden of alcohol-related liver disease and hepatitis infections globally is further fueling treatment demand.

Pharmaceutical companies are investing in novel medicinal therapies to manage fluid accumulation more effectively, reducing the need for repeated invasive procedures.

Market Segmentation by Treatment and Diagnosis

By treatment, the market includes medicinal therapy, surgery, paracentesis, and others. Medicinal therapy dominates due to widespread use of diuretics and supportive drugs. However, paracentesis remains a critical procedure for severe fluid accumulation cases.

Diagnosis methods include ultrasound, CT scan, MRI, blood tests, laparoscopy, angiography, and others. Ultrasound is the most commonly used diagnostic tool due to its cost-effectiveness and accessibility.

Route of Administration and End User Insights

Based on route of administration, the market is segmented into oral, parenteral, and others. Oral medications hold a significant share, while parenteral routes are used in advanced cases.

Hospitals and clinics account for the largest end-user segment due to the need for specialized diagnostic and therapeutic procedures. Research and academic laboratories are also contributing through clinical studies and drug development.

Request sample report Explore

Regional and Competitive Landscape

North America leads the market due to advanced healthcare systems, followed by Europe and Asia Pacific. Latin America and the Middle East & Africa are witnessing steady growth.

Major companies operating in the market include Becton, Dickinson and Company, BioVie Inc., Sequana Medical NV, Sanofi Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., and WOCKHARDT.